向日葵“忽悠式重组”被立案调查 资产重组终止

Core Viewpoint - Zhejiang Sunflower (向日葵) is under investigation by the China Securities Regulatory Commission (CSRC) for allegedly misleading statements in its restructuring plan, which has raised market concerns regarding the actual production capacity and business model of the targeted assets [1][2]. Group 1: Investigation Details - On January 14, Zhejiang Sunflower received a notice from the CSRC regarding the formal investigation due to suspected violations of information disclosure laws [2]. - The company announced the termination of its asset restructuring plan, stating it no longer meets the conditions for issuing shares to purchase assets following the CSRC's notice [2][3]. Group 2: Business Overview - Zhejiang Sunflower focuses on the pharmaceutical sector, primarily engaged in the research, manufacturing, and sales of drugs for infections, cardiovascular diseases, and digestive systems [2]. - The restructuring plan aimed to acquire 100% of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd., intending to expand into the high-end semiconductor materials sector [3]. Group 3: Market Reaction and Financial Performance - Following the announcement of the investigation, Zhejiang Sunflower's stock price fell by 20%, closing at 4.96 yuan per share, with a total market capitalization of 6.385 billion yuan [5]. - The company's financial performance has been under pressure, with a reported revenue of 19.952 million yuan for the first three quarters of 2025, a year-on-year decline of 12.09%, and a net profit attributable to shareholders of 1.3062 million yuan, down 53.10% year-on-year [5].